N/A N=54 Skin Care Behaviors Among Melanoma Survivors and Their Families
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=600 Skin Health Online for Melanoma: Better Risk Assessment
Melanoma (Skin)
Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants
N/A N=1,000 Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access
Melanoma
Primary: Number of Participants Who Completed SSE at Specified Time Points — 217; 242; 475; 238 Participants — p=<0.001
N/A N=100 Melanoma Perception and Health Literacy in People of Color
Melanoma
Primary: Number of Participants That Performed Regular Self-Skin Examinations — 8; 16; 23; 25 participants — p=0.048
N/A N=368 Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
N/A N=54 Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Cutaneous Melanoma
Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05
N/A N=75,771 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer
Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants
N/A N=441 Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma
Stage 0 Skin Melanoma · Stage I Skin Melanoma · Stage IA Skin Melanoma
Primary: Sun Protection Behavior Index — 3.54; 3.37 scores on a scale
N/A N=420 Skin Self-Examination Education During Mammography
Melanoma
Primary: Number of Participants That Performed a Skin Self-Examination at 3-months — 161; 185 Participants — p=0.12
N/A N=2,054 Using MC1R Genotype to Impact Melanoma Risk Behavior
Melanoma (Skin) · Squamous Cell Carcinoma · Squamous Cell Cancer
Primary: Weekday Sun Exposure - NHW - Baseline — 1.27; 1.30; 1.26; 1.29 Hours
N/A N=149 SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer
Skin Cancer
Primary: Accuracy of Skin Cancer Diagnosis: In-Person Assessment — 93 percentage of skin lesions
Phase 2 N=104 Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants
Phase 2 N=100 Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
Patients at Risk for Melanoma
Primary: UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi — 94.6; 96.2; 33.6; 33.1 percentage of 8-OG expression in nevi — p=.65
N/A N=105 AI-based Medical Device Validation for Early Melanoma Detection
Melanoma · Melanoma, Skin
Primary: Area Under the ROC Curve (AUC) for Melanoma Detection — 0.8482 Probability area (value from 0 to 1)
Phase 2 N=138 Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Melanoma
Primary: Immunologic Response Rate — 7; 1; 0; 0 Participants
Phase 2 N=80 Lovastatin in Treating Patients At High Risk of Melanoma
Precancerous Condition · Stage 0 Melanoma · Stage I Melanoma
Primary: Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation — 0.50; -0.12 score
N/A N=14,381 The Impact of Total Body Skin Examination on Skin Cancer Detection
Melanoma · Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body. — 810; 631 participants — p=<0.01
Phase 2 N=50 Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Precancerous Condition
Primary: Sulindac Concentration in the Nevi (Moles) — 0.51; 0 µg/g tissue
N/A N=92 Risk Information and Skin-cancer Education for Undergraduate Prevention
Melanoma · Young Adult
Primary: Sun Protection Behaviors Assessed Via Questionnaires — 2.4; 3.0; 2.8; 2.3 score on a scale
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
Phase 3 N=1,383 Evaluation of Pigmented Skin Lesions With MelaFind(R) System
Melanoma
Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05
N/A N=41 Using Physical Tracking to Predict Sunburn
Prevention
Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day
N/A N=40 Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
Actinic Keratosis
Primary: Changes From Baseline in Actinic Keratosis - Lesion Base Count. — 1.15; 2.65; 1.15; 2.60 lesions — p=<0.001
N/A N=75 Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
Squamous Cell Carcinoma
Primary: Number of Control and Intervention Participants on Skin Self-examination Performance at Follow-up 1 Month After Intervention — 34; 8 Participants
N/A N=100 Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.
Melanoma (Skin)
Primary: The Percentage of Eligible and Contacted Patients Who Were Randomised Into the Trial — 100 Participants
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
Phase 2 N=3 Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
N/A N=130 Partner Assistance in Learning and Performing Skin Self-Examination
Melanoma
Primary: Mean Number of Skin Examinations Without Partner Over 4 Months — 0.02; 0.00; 0.02; 0.00 Times examined skin by self
N/A N=197 The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention
Skin Cancer Prevention
Primary: Sun Stage of Change at 3 Months — 17; 5; 10; 12 Participants
Phase 2 N=14 Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
Pediatric Cancer · CNS Tumor, Childhood · Skin Inflammation
Primary: Rate of Cutaneous Reaction — 7 Participants